Dyadic International, Inc. (OTCMKTS:DYAI) recently announced that they have entered into an R&D agreement to advance its proprietary C1 fungal strain for biopharmaceutical development & production.
JUPITER, Fla., Sept. 07, 2016 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”) (DYAI), a global biotechnology company focused on the development and large scale manufacture of low cost, better performing biologic vaccines and drugs at flexible commercial scales, today announced they have entered into a research and development agreement to further advance its proprietary C1 fungal strain for biopharmaceutical development & production. The collaboration is targeting the development of highly productive C1 strains & fermentation processes, and the accompanying associated molecular tools to produce a number of targeted therapeutic proteins for Dyadic as well as those specified by third party biotech and pharmaceutical companies.
“We are excited to be further advancing C1’s capabilities for the development and production of lower cost therapeutic proteins,” said Mark A. Emalfarb, Founder and CEO, Dyadic. “In order to reach our ambitious goals and to incentivize the scientists carrying out this project, the agreement provides for potential milestone payments for achieving specified productivity levels and glycosylation properties within specified timelines.”
“The research & development program will encompass the entire spectrum of strain development through fermentation optimization, applying proven scientific and genetic techniques and principles, executed by some of the most skilled filamentous fungal researchers to re-engineer the highly productive industrially proven C1 expression system for therapeutic uses,” said Ronen Tchelet, PhD, Dyadic’s VP of Research & Business Development. “What we are setting out to accomplish in this development program has the potential to help bring biologic vaccines & drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers and, hopefully, improve access and reduce cost to patients and the healthcare system, but most importantly saving lives.”
About Dyadic International, Inc.
Dyadic International, Inc. is a global biotechnology company which is developing what it believes will be a potentially significant biopharmaceutical protein production system based on the fungus Myceliopthora thermophila, nicknamed C1. The C1 microorganism, which enables the development and large scale manufacture of low cost proteins, has the potential to be further developed into a safe and efficient expression system that may help speed up the development, production and performance of biologic vaccines and drugs at flexible commercial scales. Dyadic is using the C1 technology and other technologies to conduct research, development and commercial activities for the development and manufacturing of human and animal vaccines, monoclonal antibodies, biosimilars and/or biobetters, and other therapeutic proteins. Dyadic pursues research and development collaborations, licensing arrangements and other commercial opportunities with its partners and collaborators to leverage the value and benefits of these technologies in developing and manufacturing biopharmaceuticals which these technologies help produce. In particular, as the aging population grows in developed and undeveloped countries, Dyadic believes the C1 technology may help bring biologic drugs to market faster, in greater volumes, at lower cost, and with new properties to drug developers and manufacturers and, hopefully, improve access and cost to patients and the healthcare system, but most importantly saving lives. Please visit Dyadic’s website at www.dyadic.com for additional information, including details regarding Dyadic’s plans for its biopharmaceutical business.
Dyadic trades on the OTCQX tier of the OTC marketplace. Investors can find real-time quotes, market information and financial reports for Dyadic, as well as additional information related to its professional liability lawsuit, in the company’s annual and quarterly reports which are filed with the OTC markets. Please visit the OTC markets website at www.otcmarkets.com/stock/DYAI/quote.
The mathematical calculation that represents the degree of change over time is known as “percentage change”. In finance, it serves many purposes, and is often used to represent the price change of a commodity.
Percentage change can be applied to any quantity that is measured over time any given time period. Say you are tracking the price of a stock. If the price increased, the formula [(New Price – Old Price)/Old Price] is applied and then take that number and multiply it by 100. If the price of a stock decreased, the formula [(Old Price – New Price)/Old Price] is applied then multiplied by 100.
The formula can be used to track the prices of both individual commodities and large market listings, and also used to compare the values of different currencies. Balance sheets with comparative financial statements often will include prices of specific stocks at different time periods alongside the percentage change over the same periods of time. Over the past three months, Dyadic International, Inc. (OTCMKTS:DYAI) has seen 363500 shares trade hands on average.
Are Dyadic International, Inc. (OTCMKTS:DYAI) Shares Ready to Explode? Sign up to our Newsletter to be the First to Know
Sign up to get our Free Penny Stock Picks Before the Street!
Dyadic International, Inc. (OTCMKTS:DYAI) shares closed the most recent session at $1.43, moving from the previous open of $-0.02. This is compared to the stock’s 52-week high of 1.85 and 52-week low of 0.81.
Companies are ranked according to their market caps, falling into large-cap, mid-cap and small-cap categories.
Large-cap companies have a market cap north of $10 billion. These large companies have usually been in business for a long time, and are major participants in well-established sectors. Investors in large-cap companies don’t necessarily bank large returns in short time periods, though are rewarded with a constant increase in share value over the long run.
Mid-cap companies have a market cap of $2 billion – $10 billion. Mid-cap companies are usually established companies operating in an industry that is expected to experience quick growth. Mid-cap companies are usually in the middle of expansion. They carry higher risk than large-cap companies due to the fact that they are not as established, though their growth potential remains an attraction to investors.
Small-cap companies have a market cap of $300 million – $2 billion. These smaller companies are usually newer or perhaps service a niche market or a new industry. Generally considered to be a higher risk than mid or large-cap in part because of their age, their size and the markets they serve. Small-cap companies usually have fewer resources and are more sensitive to the ebb-and-flow of markets. Dyadic International, Inc. (OTCMKTS:DYAI)’s market cap currently sits at $51850000.
Sign Up to Receive Breaking Alerts on Stocks That Are Primed to Make a Run in the Bar Below.
Sign up to get our Free Penny Stock Picks Before the Street!
Disclaimer: The advice provided on this website is general advice only. It has been prepared without taking into account your objectives, financial situation or needs. Before acting on this advice you should consider the appropriateness of the advice, having regard to your own objectives, financial situation and needs. Where quoted, past performance is not indicative of future performance.
BRKK is One of the Most Under the Radar Penny Stocks We've Ever Seen. View the free report here.